Researchers have identified a strategy to repurpose anthracyclines for use in advanced, drug-resistant head and neck squamous cell carcinomas (HNSCC). The research found the transcriptional inhibitor E2F7 is mislocalised to the cytoplasm in more than 80% of human HNSCCs. Meanwhile its counterpart, the transcriptional activator E2F1, retains localisation in the nucleus of the cancer cells ...
Associate Professor Nicholas Saunders: Resetting the drivers of anthracycline resistance
By Mardi Chapman
18 Jul 2018